Lv34
308 积分 2021-10-31 加入
366 (PB354): Preclinical evaluation of TTR-201, a novel ferrous-iron responsive (FIRE) conjugate of the topoisomerase-I inhibitor exatecan
22天前
已完结
520LBA (PB-520) LBA Posters: Preclinical characterization of LY4175408, a novel PTK7 targeting antibody-drug conjugate, utilizing exatecan via a hydrophilic polysarcosine linker platform
22天前
已完结
Spotlight on Ideal Target Antigens and Resistance in Antibody-Drug Conjugates: Strategies for Competitive Advancement
28天前
已完结
A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer
1个月前
已完结
A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
1个月前
已完结
Cancer‐associated fibroblasts at the unfavorable desmoplastic stroma promote colorectal cancer aggressiveness: Potential role ofADAM9
1个月前
已完结
A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer
1个月前
已完结
Novel antibody-drug conjugate based on DXd-ADC technology
2个月前
已完结
Kinetic measurements of human CD8+ T cell cytotoxic activity in a 384-well plate format
2个月前
已完结
Tumor Infiltrating T Cell Cytotoxicity Assay
2个月前
已完结
皖公网安备34019202002308
